Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Cascade Impactor Equivalence Testing: Comparison of the Performance of the Modified Chi-Square Ratio Statistic (mCSRS) with the Original CSRS and EMA's Average Bioequivalence Approach.

Kurumaddali A, Christopher D, Sandell D, Strickland H, Morgan B, Bulitta J, Wiggenhorn C, Stein S, Lyapustina S, Hochhaus G.

AAPS PharmSciTech. 2019 Jul 8;20(6):249. doi: 10.1208/s12249-019-1443-7.

PMID:
31286316
2.

Pharmacokinetic and pharmacodynamic modeling of gut hormone peptide YY(3-36) after pulmonary delivery.

Shao J, Chen MJ, Kuehl PJ, Hochhaus G.

Drug Dev Ind Pharm. 2019 Jul;45(7):1101-1110. doi: 10.1080/03639045.2019.1593443. Epub 2019 Apr 30.

PMID:
31039626
3.

Fetal Concentrations of Budesonide and Fluticasone Propionate: a Study in Mice.

Zaidi S, Chen MJ, Lee DT, Neubart E, Ewing P, Miller-Larsson A, Hochhaus G.

AAPS J. 2019 Apr 16;21(4):53. doi: 10.1208/s12248-019-0313-2.

PMID:
30993489
4.

Characterization of a dextran-budesonide prodrug for inhalation therapy.

Waters RC, Hochhaus G.

Eur J Pharm Sci. 2019 Mar 1;129:58-67. doi: 10.1016/j.ejps.2018.11.038. Epub 2018 Dec 4.

PMID:
30521945
5.

Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers.

Bhagwat S, Schilling U, Chen MJ, Wei X, Delvadia R, Absar M, Saluja B, Hochhaus G.

Pharm Res. 2017 Dec;34(12):2541-2556. doi: 10.1007/s11095-017-2235-y. Epub 2017 Aug 10.

PMID:
28799097
6.

Effects of lipid formulations on clove extract spray dried powders: comparison of physicochemical properties, storage stability and in vitro intestinal permeation.

Cortes-Rojas DF, Souza CRF, Chen MJ, Hochhaus G, Oliveira WP.

Pharm Dev Technol. 2018 Dec;23(10):1047-1056. doi: 10.1080/10837450.2017.1314491. Epub 2017 Apr 19.

PMID:
28368215
7.

Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator.

Jung JI, Price AR, Ladd TB, Ran Y, Park HJ, Ceballos-Diaz C, Smithson LA, Hochhaus G, Tang Y, Akula R, Ba S, Koo EH, Shapiro G, Felsenstein KM, Golde TE.

Mol Neurodegener. 2015 Jul 14;10:29. doi: 10.1186/s13024-015-0021-z.

8.

Quantitative characterization of circadian rhythm of pulmonary function in asthmatic patients treated with inhaled corticosteroids.

Zhou D, Li H, Wang Y, Hochhaus G, Sinha V, Zhao L.

J Pharmacokinet Pharmacodyn. 2015 Aug;42(4):391-9. doi: 10.1007/s10928-015-9420-6. Epub 2015 Jun 23.

PMID:
26099861
9.

Evaluation of the Transwell System for Characterization of Dissolution Behavior of Inhalation Drugs: Effects of Membrane and Surfactant.

Rohrschneider M, Bhagwat S, Krampe R, Michler V, Breitkreutz J, Hochhaus G.

Mol Pharm. 2015 Aug 3;12(8):2618-24. doi: 10.1021/acs.molpharmaceut.5b00221. Epub 2015 Jul 9.

PMID:
26091361
10.

Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference.

Hochhaus G, Davis-Cutting C, Oliver M, Lee SL, Lyapustina S.

AAPS J. 2015 Sep;17(5):1305-11. doi: 10.1208/s12248-015-9791-z. Epub 2015 Jun 2.

12.

Pharmacokinetics of Orally Inhaled Drug Products.

Hochhaus G, Horhota S, Hendeles L, Suarez S, Rebello J.

AAPS J. 2015 May;17(3):769-75. doi: 10.1208/s12248-015-9736-6. Epub 2015 Mar 12.

13.

Application of the modified chi-square ratio statistic in a stepwise procedure for cascade impactor equivalence testing.

Weber B, Lee SL, Delvadia R, Lionberger R, Li BV, Tsong Y, Hochhaus G.

AAPS J. 2015 Mar;17(2):370-9. doi: 10.1208/s12248-014-9698-0. Epub 2014 Dec 17.

14.

Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.

Hurtado FK, Weber B, Derendorf H, Hochhaus G, Dalla Costa T.

Antimicrob Agents Chemother. 2014;58(2):678-86. doi: 10.1128/AAC.01884-13. Epub 2013 Nov 11.

15.

Pharmacokinetics and pharmacodynamics of glycopyrrolate following a continuous-rate infusion in the horse.

Rumpler MJ, Kandala B, Vickroy TW, Hochhaus G, Sams RA.

J Vet Pharmacol Ther. 2014 Apr;37(2):133-44. doi: 10.1111/jvp.12074. Epub 2013 Jul 31.

PMID:
23902283
16.

Development of a placebo effect model combined with a dropout model for bipolar disorder.

Sun W, Laughren TP, Zhu H, Hochhaus G, Wang Y.

J Pharmacokinet Pharmacodyn. 2013 Jun;40(3):359-68. doi: 10.1007/s10928-013-9305-5. Epub 2013 Mar 2.

PMID:
23456101
17.

Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives.

Apiou-Sbirlea G, Newman S, Fleming J, Siekmeier R, Ehrmann S, Scheuch G, Hochhaus G, Hickey A.

Ther Deliv. 2013 Mar;4(3):343-67. doi: 10.4155/tde.12.161. Review.

PMID:
23442081
18.

A sensitivity analysis of the modified chi-square ratio statistic for equivalence testing of aerodynamic particle size distribution.

Weber B, Lee SL, Lionberger R, Li BV, Tsong Y, Hochhaus G.

AAPS J. 2013 Apr;15(2):465-76. doi: 10.1208/s12248-013-9453-y. Epub 2013 Jan 24.

19.

A pharmacokinetic simulation tool for inhaled corticosteroids.

Weber B, Hochhaus G.

AAPS J. 2013 Jan;15(1):159-71. doi: 10.1208/s12248-012-9420-z. Epub 2012 Nov 10.

20.

Pharmacokinetic evaluation of visnagin and Ammi visnaga aqueous extract after oral administration in rats.

Haug KG, Weber B, Hochhaus G, Butterweck V.

Planta Med. 2012 Nov;78(17):1831-6. doi: 10.1055/s-0032-1315393. Epub 2012 Oct 24. Erratum in: Planta Med. 2013 Mar;79(3-4):312.

PMID:
23096256
21.

A stability analysis of a modified version of the chi-square ratio statistic: implications for equivalence testing of aerodynamic particle size distribution.

Weber B, Hochhaus G, Adams W, Lionberger R, Li B, Tsong Y, Lee SL.

AAPS J. 2013 Jan;15(1):1-9. doi: 10.1208/s12248-012-9410-1. Epub 2012 Sep 25.

22.

Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report.

Evans C, Cipolla D, Chesworth T, Agurell E, Ahrens R, Conner D, Dissanayake S, Dolovich M, Doub W, Fuglsang A, García Arieta A, Golden M, Hermann R, Hochhaus G, Holmes S, Lafferty P, Lyapustina S, Nair P, O'Connor D, Parkins D, Peterson I, Reisner C, Sandell D, Singh GJ, Weda M, Watson P.

J Aerosol Med Pulm Drug Deliv. 2012 Jun;25(3):117-39. doi: 10.1089/jamp.2011.0968. Epub 2012 Mar 13.

PMID:
22413806
23.

Nonlinear pharmacokinetics of visnagin in rats after intravenous bolus administration.

Haug KG, Weber B, Hochhaus G, Butterweck V.

Eur J Pharm Sci. 2012 Jan 23;45(1-2):79-89. doi: 10.1016/j.ejps.2011.10.023. Epub 2011 Nov 9.

PMID:
22085634
24.

Systemic exposure to fluticasone MDI delivered through antistatic chambers.

Elmallah MK, Khan Y, Hochhaus G, Shuster JJ, Hendeles L.

J Allergy Clin Immunol. 2011 Nov;128(5):1113-5.e1-3. doi: 10.1016/j.jaci.2011.06.014. Epub 2011 Jul 23. No abstract available.

25.
26.

Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report.

O'Connor D, Adams WP, Chen ML, Daley-Yates P, Davis J, Derendorf H, Ducharme MP, Fuglsang A, Herrle M, Hochhaus G, Holmes SM, Lee SL, Li BV, Lyapustina S, Newman S, Oliver M, Patterson B, Peart J, Poochikian G, Roy P, Shah T, Singh GJ, Sharp SS.

J Aerosol Med Pulm Drug Deliv. 2011 Jun;24(3):119-35. doi: 10.1089/jamp.2011.0878. Epub 2011 Mar 31.

PMID:
21453049
27.

Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant.

Pinto E, Zhang B, Song S, Bodor N, Buchwald P, Hochhaus G.

Pharmazie. 2010 Jun;65(6):429-35.

PMID:
20614691
28.

Feasibility of localized immunosuppression: 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation.

Buchwald P, Bocca N, Marzorati S, Hochhaus G, Bodor N, Stabler C, Kenyon NS, Inverardi L, Molano RD, Ricordi C, Pileggi A.

Pharmazie. 2010 Jun;65(6):421-8.

PMID:
20614690
29.

Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.

Adams WP, Ahrens RC, Chen ML, Christopher D, Chowdhury BA, Conner DP, Dalby R, Fitzgerald K, Hendeles L, Hickey AJ, Hochhaus G, Laube BL, Lucas P, Lee SL, Lyapustina S, Li B, O'Connor D, Parikh N, Parkins DA, Peri P, Pitcairn GR, Riebe M, Roy P, Shah T, Singh GJ, Sharp SS, Suman JD, Weda M, Woodcock J, Yu L.

J Aerosol Med Pulm Drug Deliv. 2010 Feb;23(1):1-29. doi: 10.1089/jamp.2009.0803.

PMID:
20131983
30.

Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole.

Afzal A, Caballero S, Palii SS, Jurczyk S, Pardue M, Geroski D, Edelhauser H, Hochhaus G, Kim M, Franklin A, Shapiro G, Grant MB.

Brain Res Bull. 2010 Feb 15;81(2-3):320-6. doi: 10.1016/j.brainresbull.2009.08.001. Epub 2009 Aug 11.

31.

Budesonide and ciclesonide: effect of tissue binding on pulmonary receptor binding.

Wu K, Blomgren AL, Ekholm K, Weber B, Edsbaecker S, Hochhaus G.

Drug Metab Dispos. 2009 Jul;37(7):1421-6. doi: 10.1124/dmd.108.026039. Epub 2009 Apr 13.

PMID:
19364829
32.

Chronic blockade of hindbrain glucocorticoid receptors reduces blood pressure responses to novel stress and attenuates adaptation to repeated stress.

Bechtold AG, Patel G, Hochhaus G, Scheuer DA.

Am J Physiol Regul Integr Comp Physiol. 2009 May;296(5):R1445-54. doi: 10.1152/ajpregu.00095.2008. Epub 2009 Mar 11.

33.

Transrepression and transactivation potencies of inhaled glucocorticoids.

Dirks NL, Li S, Huth B, Hochhaus G, Yates CR, Meibohm B.

Pharmazie. 2008 Dec;63(12):893-8.

PMID:
19177906
34.

Relative receptor affinity comparisons among inhaled/intranasal corticosteroids: perspectives on clinical relevance.

Hochhaus G.

Respir Res. 2008 Nov 24;9:75. doi: 10.1186/1465-9921-9-75. No abstract available.

36.

Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor.

Palii SS, Afzal A, Shaw LC, Pan H, Caballero S, Miller RC, Jurczyk S, Reubi JC, Tan Y, Hochhaus G, Edelhauser H, Geroski D, Shapiro G, Grant MB.

Invest Ophthalmol Vis Sci. 2008 Nov;49(11):5094-102. doi: 10.1167/iovs.08-2289. Epub 2008 Jul 3.

PMID:
18599562
37.

Slow release formulations of inhaled rifampin.

Coowanitwong I, Arya V, Kulvanich P, Hochhaus G.

AAPS J. 2008 Jun;10(2):342-8. doi: 10.1208/s12248-008-9044-5. Epub 2008 Jun 27.

38.

Fluticasone furoate nasal spray in allergic rhinitis.

Goyal N, Hochhaus G.

Drugs Today (Barc). 2008 Apr;44(4):251-60. Review.

PMID:
18536783
39.

Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy.

Hochhaus G.

Clin Ther. 2008 Jan;30(1):1-13. doi: 10.1016/j.clinthera.2008.01.005. Review.

PMID:
18343239
40.

Pharmacokinetics and pharmacodynamics of inhaled glucocorticoids.

Padden J, Skoner D, Hochhaus G.

J Asthma. 2008;45 Suppl 1:13-24.

PMID:
19093281
41.

Laser-ablated nanofunctional polymers for the formulation of slow-release powders for dry powder inhalers: physicochemical characterization and slow-release characteristics.

Coowanitwong I, Arya V, Patel G, Kim WS, Craciun V, Rocca JR, Singh R, Hochhaus G.

J Pharm Pharmacol. 2007 Nov;59(11):1473-84.

PMID:
17976257
42.

Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction.

Mortimer KJ, Tattersfield AE, Tang Y, Wu K, Lewis S, Hochhaus G, Harrison TW.

Br J Clin Pharmacol. 2007 Oct;64(4):439-44. Epub 2007 Aug 15.

43.

Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.

Tayab ZR, Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ, Hochhaus G.

Br J Clin Pharmacol. 2007 Nov;64(5):698-705. Epub 2007 May 17.

44.

Advances in single-entity inhaled corticosteroid therapy.

Tayab ZR, Hochhaus G.

Allergy Asthma Proc. 2007 Mar-Apr;28(2):125-35. Review.

PMID:
17479595
45.

Pulmonary targeting of sustained release formulation of budesonide in neonatal rats.

Arya V, Coowanitwong I, Brugos B, Kim WS, Singh R, Hochhaus G.

J Drug Target. 2006 Dec;14(10):680-6.

PMID:
17162737
46.

Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask.

Khan Y, Tang Y, Hochhaus G, Shuster JJ, Spencer T, Chesrown S, Hendeles L.

J Pediatr. 2006 Dec;149(6):793-7.

PMID:
17137894
47.

Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma.

Mortimer KJ, Harrison TW, Tang Y, Wu K, Lewis S, Sahasranaman S, Hochhaus G, Tattersfield AE.

Br J Clin Pharmacol. 2006 Oct;62(4):412-9.

48.

Do intensive care patients need an individualized dosing regimen for levofloxacin?

Tayab ZR, Hochhaus G, Kaufmann S, Jäger D, Barth J.

Int J Clin Pharmacol Ther. 2006 Jun;44(6):262-9.

PMID:
16800098
49.

Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.

Stark JG, Werner S, Homrighausen S, Tang Y, Krieg M, Derendorf H, Moellmann H, Hochhaus G.

J Pharmacokinet Pharmacodyn. 2006 Aug;33(4):441-59. Epub 2006 Apr 22.

PMID:
16633890
50.

Pharmacological effects of some newly developed soft anticholinergics and a receptor-binding QSAR study.

Mori N, Buchwald P, Wu WM, Ji F, Hochhaus G, Bodor N.

Pharmazie. 2006 Feb;61(2):148-53.

PMID:
16526564

Supplemental Content

Loading ...
Support Center